Antimicrobial-resistant Neisseria gonorrhoeae (NG) is a global public health issue that threatens effectiveness of current treatments of NG. Increased use of nucleic acid amplification tests (NAATs) in lieu of cultures makes obtaining clinical isolates for susceptibility testing difficult and samples collected in commercial transport buffer for NAATs do not preserve viable organism, while molecular methods of assessing antibiotic susceptibility do not require viable organism. We evaluated 243 NG-positive samples in Aptima transport media including urine, oral, and rectal swabs from Nigerian men who have sex with men for markers to penicillinase-producing NG, ciprofloxacin (GyrA and ParC mutations), and extended spectrum cephalosporins (ESCs, PenA mosaic [allele X], PonA, mtrR, PorB mutations) by real-time PCR. NG DNA was recovered in 75% (183/243) of samples. Of these, 93% (171/183) were positive for at least one resistance marker. We observed a prevalence of dual resistance markers to penicillin and ciprofloxacin at 46.2% (79/171). Six percent of samples (10/171) tested positive for the PenA mosaic (allele X) ESC marker. These data indicate that antibiotic-resistant NG is common in Nigeria. Laboratory and clinical capacity building in Nigeria should include development of methods to culture NG and determine antimicrobial susceptibility.
Introduction
Neisseria gonorrhoeae (NG) is one of the most common sexually transmitted infections (STIs) in the United States and globally. [1] [2] [3] NG has been highlighted as an important public health concern due to the global spread of antimicrobial-resistant (AMR) species. Of particular concern are strains with resistance to extended spectrum cephalosporins (ESCs) such as ceftriaxone, the currently recommended treatment for NG infections. [2] [3] [4] [5] [6] [7] [8] These strains represent essentially untreatable NG, as most circulating strains of NG are resistant to penicillin and many are resistant to ciprofloxacin and azithromycin. [2] [3] [4] [5] [6] [9] [10] [11] [12] In resource-limited settings, poor retention of patients or lack of appropriate antibiotics can make antibiotic stewardship difficult. Systematic monitoring for resistance is therefore essential. [13] [14] [15] [16] Typically, AMR is determined using agar dilution methods to determine the minimum inhibitory concentration (MIC) of each antibiotic of interest. Although this is the most accurate method of AMR determination, it can be technically challenging due to the expertise required for NG culture and identification, the precision required for antibiotic preparation, the number of antibiotic concentrations required, MIC plate preparation and interpretation. These methods require viable clinical isolates and are costly. While Etests (BioMerieux, Durham, NC) for many antibiotics are available and are less complex than agar dilution, these culture-based methods are still expensive and require viable organism from clinical isolates. 17 With the increased use of nucleic acid amplification tests (NAATs) for STI detection, clinical isolates of pathogenic organisms are infrequently available, since recovering viable organisms from commercial NAAT transport is impossible. Molecular methods that can identify single nucleotide polymorphisms (SNPs) or mutant genotype markers associated with AMR can potentially be used to overcome some of the challenges associated with traditional culture methods and without a need for viable organism from clinical isolates. [18] [19] [20] [21] [22] [23] [24] While there are limitations to the use of molecular methods for AMR screening, these methods represent a hypothetically valuable tool to gain information about AMR genotypes associated with a pathogen. 21, 24 These methods have successfully illustrated correlation with MICs, have been useful in AMR surveillance, and have also demonstrated value in terms of their impact on guiding antimicrobial therapy. 21, [25] [26] [27] Across sub-Saharan Africa, many countries employ a syndromic approach to STI management as standard of care. 16 Nigeria and other resource-limited settings do not have the infrastructure for advanced STI diagnostics. In Nigeria, men who have sex with men (MSM) and transgender women (TGW) face a particularly high burden of HIV, NG, and other STIs. 28 As such, AMR surveillance in these populations is important in order to promote the most efficacious disease treatment. We sought to determine the prevalence of AMR markers for penicillinaseproducing NG (PPNG), 19 ciprofloxacin resistance (GyrA and ParC mutations), 18 and ESCs (PenA, PonA, mtrR, and PorB) 22, 23 in PorA (PAP) pseudogene-positive samples 29 from a cohort of Nigerian MSM and TGW.
Material and methods

Study population
The Lagos site of the TRUST/RV368 cohort study enrolled MSM and TGW using respondent-driven sampling as previously described. 28, 30 Briefly, seven diverse seed participants and each subsequent enrollee were given three coupons to distribute to other MSM. Eligible participants were adults over 18 years old who presented a valid coupon and reported receptive or insertive anal intercourse with a male partner in the preceding 12 months. Participants who enrolled between 28 April 2014 and 19 July 2016 were included in these analyses.
All participants provided written informed consent before enrollment. Institutional review boards at the Nigerian Federal Capital Territory and Nigerian Ministry of Defense, Abuja, Nigeria; the University of Maryland, Baltimore, MD, USA; and the Walter Reed Army Institute of Research, Silver Spring, MD, USA approved the study.
STI testing and follow-up
Participants underwent testing for HIV and other STIs every three months for up to 18 months. Urine, oral swabs, and rectal swabs were tested for NG and Chlamydia trachomatis using the Aptima Combo 2 V R assay (Hologic, Bedford, MA). Fingerstick blood specimens were screened for HIV infection using a parallel algorithm of rapid tests with Determine V R (Alere, Waltham, MA) and Uni-gold V R (Trinity Biotech, Co., Wicklow, Ireland) kits. Testing was conducted according to package inserts. Sample stability was ensured as specimen collection was performed according to the study manual of operations, samples were collected, stored in a cooler, and transported to Lagos with the other study samples at ambient temperature [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] C. Samples were then shipped at 2-8 C to DRL Abuja for testing and long-term storage at À80 C. Samples were then shipped to Johns Hopkins University on dry ice and were stored at À80 C prior to additional testing.
Molecular testing for NG DNA and AMR
Samples that tested positive for NG by the Aptima Combo 2 V R assay underwent nucleic acid extraction utilizing the Roche MagNA Pure LC robot (Roche Diagnostics, Indianapolis, IN) with the DNA I Isolation kit, employing the blood/cells high performance protocol based on manufacturer instructions. A 200-ml sample volume with a 100-ml elution volume was used. All extraction runs contained positive (wild-type NG) and negative (molecular grade water) controls. Following nucleic acid extraction, samples were initially screened by PCR for the porA pseudogene (PAP) to ensure NG nucleic acid recovery from the Aptima Combo 2 V R transport medium. 29 Samples that were PAP positive were then screened for PPNG, GyrA and ParC mutations, as well as the PenA mosaic (allele X) sequence by real-time PCR. 18, 19, 22 Mosaic allele X was chosen as a target as the mutations associated with allele X are the most frequently reported, and testing for these mutations represents the best opportunity to determine potential cephalosporin resistance by molecular methods. Other mutations were not screened for based on frequency of occurrence and preserving sample volume. Samples that tested PenA positive underwent additional testing for mutations in the PonA, mtrR, and PorB genes. 23 Real-time PCRs used primers and probes as previously described 18, 19, 22, 23, 29 and were performed on the Applied Biosystems Quant Studio 12K Flex platform (Applied Biosystems, Foster City, CA) as follows, with minor modification from previous conditions: all reactions had a final volume of 50 ml with 10 ml of sample and 40 ml of mastermix. The mastermix included 25 ml of Taqman Fast Advanced Mastermix (Applied Biosystems), 2 ml of each appropriate primer and probe, 2 ml of 25 mM MgCl 2À , and nuclease-free water to make a final volume of 40 ml. Cycling conditions for the PAP, PPNG, and initial PenA screening PCRs were as follows: 95 C for 20 s, followed by 40 cycles of 95 C for 1 s, and 60 C for 30 s. Samples that tested positive for the PenA mosaic sequence underwent additional PCRs for PonA, mtrR, and PorB as follows: 95 C for 20 s, followed by 40 cycles of 95 C for 1 s, and 60 C for 1 min. PCR conditions for the GyrA and ParC assays were as follows: 95 C for 20 s, followed by 40 cycles of 95 C for 15 s, 60 C for 30 s, and 72 C for 30 s. Positive reactions were defined as PCR reactions having a C t value of <40.
In order to exclude the possibility of false-positive findings due to cross-reactivity with near neighbor bacterial species, whole genome sequencing (WGS) of NG DNA at Rocky Mountain Laboratories (RML, Hamilton, MT) was attempted for samples testing positive for the PenA mosaic sequence for confirmation of real-time PCR results. Without viable organism to perform additional testing, WGS would ensure the realtime PCR results indicating PenA mosaic sequences, as well as SNP sequences for PonA, mtrR, and PorB were associated with the NG present in the samples tested, or would indicate these results were false positives associated with near-neighbor bacterial species present in the samples that can harbor the same mutations. 21, 23 WGS for NG NGS libraries were prepared using 210 ng of DNA from each sample following the 550 bp option of the TruSeq Nano DNA Sample Preparation Guide (Illumina). Samples were sheared on a Covaris LE220 using the manufacturer recommended settings. Samples were barcoded and pooled and sequenced on an Illumina MiSeq at 2 Â 300 paired-end reads. Sequencing resulted in 24 million raw reads with 22.5 million reads passing filter. Raw reads were trimmed for adapter sequence, low quality bases, and filtered for overall low quality. Resulting reads were mapped to the NG NCCP11945 genome (NC_011035.1 and NC_011034.1) using Bowtie2 and Kraken.
Results
Study population demographics and STI testing
A total of 420 participants (128 HIV uninfected, 292 HIV infected) underwent STI testing and 37% (157/ 420) of participants had NG infections as determined by NAATs; additionally, 10% (43/420) of participants were NG positive as well as positive for C. trachomatis by NAATs, which resulted in 243 samples for AMR evaluation with real-time PCR, as some participants were NG positive at more than one anatomic site. Participant demographics are summarized in Table 1 . Of the 243 positive samples, 67% (163/243) were positive for one anatomic site sample, while 17% (42/243) were positive for both oral and rectal samples, 9% (22/243) were positive for urine and rectal samples, 2% (4/243) were positive for urine and oral samples, and 5% (12/ 243) were positive for all three samples collected.
Real-time PCR for molecular AMR markers
NG DNA was successfully recovered in 75% (183/243) of the samples as these samples tested positive for PAP post DNA extraction. Of these, 93% (171/183) were positive for at least one resistance marker. Overall, 73.6% (126) tested positive for PPNG indicating resistance to penicillin, and 67% (114) tested positive for mutations in GyrA associated with ciprofloxacin resistance (Figures 1 and 2) .
By sample type, oral swab samples tested positive in 12.8% (22), 3.5% (6), and 2.4% (4) for PPNG; GyrA mutations; and GyrA/ParC double mutations, respectively. For urine samples, 7.6% (13), 9.9% (17), and 8.2% (14) tested positive for PPNG; GyrA mutations; and GyrA/ParC double mutations, respectively. Lastly, for rectal swabs, 56.1% (96), 56.1% (96) and 46.7% (80) tested positive for PPNG, GyrA mutations, and GyrA/ParC double mutations, respectively ( Figure  3 ). For individuals infected with NG at more than one anatomic site, 47.4% (18/38) had the same results for PPNG (N ¼ 13), GyrA and ParC (N ¼ 5) across different anatomic sites.
Ten
Additional testing for mutations in PonA, mtrR, and PorB was performed on the ten samples that were positive for the PenA mosaic (allele X) sequence (Table 2) . 23 Of these, multiple samples tested positive for both wild-type and mutant sequences simultaneously, notably for PonA and mtrR. Only one of these samples tested positive for wild-type PorB. For the additional PenA testing, only two samples that initially tested as positive for the PenA mosaic (allele X), repeated as positive for the mosaic (allele X) sequence Table 2 . PPNG: penicillinase-producing NG. with an alternate assay. Seven tested positive for wild-type PenA by the additional assays. WGS mapping efficiency of reads to the NG genome was between 0.001 and 0.178% with the majority of reads mapping the human genome.
Discussion
In this study we assessed the prevalence of AMR markers associated with decreased susceptibility to penicillin, ciprofloxacin, and ESCs in 243 samples in Table 2 . PPNG: penicillinase-producing NG.
Aptima Combo 2 transport media from 157 NG-infected MSM using multiple real-time PCR assays. We found a high prevalence of molecular markers associated with AMR, mostly affecting susceptibility to penicillin and ciprofloxacin, particularly in the rectal swab samples analyzed. Previous studies of AMR in sub-Saharan Africa have illustrated varying rates of AMR, depending on the population. For example, reported rates of ciprofloxacin resistance have included 6.1-18.6% in Zimbabwe, 14, 15 28 .6% in Ethiopia, 31 83.1% among Ugandan female sex workers, 32 100% in a small study in Ghana, 33 and 53.2% in Kenya. 34 Although AMR studies specific to Nigeria are limited, a 2001 study indicated >90% of samples analyzed were susceptible to ciprofloxacin, although that study only examined 31 samples. 35 In contrast, we found 67% (114/117) of the samples evaluated in this study tested positive for markers associated with ciprofloxacin resistance, and greater than 50% of the samples positive for mutations associated with ciprofloxacin resistance were from the rectal swabs analyzed in this study. It is possible that AMR prevalence in Nigeria has increased over time.
Neither of the two studies from Zimbabwe included susceptibility testing for penicillin, as they screened for resistance to kanamycin, but our study found a relatively high number of samples that were positive for PPNG and were double mutants for GyrA and ParC. The additional studies performed in Ethiopia, Uganda, Ghana, and Kenya, all analyzed different antibiotics, but each study screened for AMR to antibiotics that would be traditionally used to treat NG. 14, 15, [31] [32] [33] [34] These prior studies each relied on agar dilution MIC or Etest to assess AMR, in contrast to the molecular techniques employed in this study. As such, it is difficult for direct comparison of our methods to agar dilutions or Etests employed in other studies. It should also be noted that the participants in this study were exclusively MSM and TGW, while the other studies focused on broader populations, and population differences could impact AMR prevalence. Additionally, these prior studies sampled limited anatomic sites, generally not including rectal or oral sampling, whereas our study universally screened participants for infection at the urethral, rectal, and oral sites.
By sample type, we found the highest percentages of positives for PPNG, as well as GyrA and ParC mutations in rectal swab samples as opposed to oral or urine samples, indicating that rectal swabs are a sample type of paramount importance for NG and AMR surveillance efforts in high-risk populations, but in MSM in particular.
The data generated from screening samples in this study for the PenA mosaic sequence suggested the possibility of ESC resistance but were ultimately inconclusive. Resistance in NG to ESCs has not yet been reported in many regions in Africa, although multidrug-resistant NG has been reported in South Africa. [14] [15] [16] [31] [32] [33] [34] 36 When molecular testing for markers associated with resistance to ESCs included testing with additional assays, 23 results were still inconclusive as the majority of samples simultaneously tested positive for both wild-type and SNP sequences ( Table 2 ). This is likely because of the presence of mixed bacterial species in these specimens rather than pure NG cultures, including both near-neighbor Neisseria species as well as other commensal bacteria that potentially have acquired these resistance factors. This is supported by This table presents results from molecular screening performed initially for the PenA mosaic (allele X) sequence (1 -reference 22), and expanded molecular testing for additional PenA (allele X), PonA, mtrR, and PorB mutations (2 -reference 23). Shaded boxes represent assay results that were positive for the listed wild-type (WT) or single nucleotide polymorphism (SNP). Samples were either rectal swab samples (N ¼ 7, samples 1-7) or urine samples (N ¼ 3, samples [8] [9] [10] .
the fact that the additional assays employed are capable of cross-reacting with other bacterial species. 23 The samples initially testing positive for the PenA mosaic sequence in this study were either rectal swabs (N ¼ 7) or urine samples (N ¼ 3), which can contain mixed bacterial species, including near neighbor Neisseria species, and although none of these samples were oral swabs, the same conclusions regarding the bacterial composition would apply to oral samples as well. WGS did not provide additional information regarding the NG in these samples as not enough NG DNA could be recovered. This is possibly because of the use of clinical swab samples as opposed to clinical isolates, as a clinical NG isolate would concentrate the amount of viable pure NG present in the sample and would remove interference from the presence of the human genome or nonpathogenic organisms in sequencing efforts. WGS has shown promise to be a predictive tool for AMR in NG when performed using clinical culture isolates. 37 There are several limitations to this study. First, NG DNA was successfully recovered from only 75% of samples. The samples utilized in these analyses were clinical swabs that contained not only the organism of interest (NG), but also human epithelial cells and organisms from other commensal bacterial species. The presence of these additional cellular types can complicate molecular testing, particularly in assays where the target can be found across multiple species. Clinical isolates, in this instance, the isolated NG organism, are typically utilized for AMR determination as this approach ensures that AMR is determined only for the pure organism of interest. Without clinical isolates, we could not perform traditional AMR determination by culture and MIC to verify the accuracy of the molecular methods employed here. Additionally, the molecular methods used in this study were all developed using clinical isolates or NG organism with previous AMR data available, making application of the sensitivity and specificity of these assays to this study's swabs problematic. However, previous studies have demonstrated strong agreement between molecular methods and traditional methods for assessing AMR. 21, 24 The data generated by assays for wild-type and SNP sequences of PenA, PonA, mtrR, and PorB as well as the poor quality results from WGS are illustrative of the limitations in applying molecular assays for resistance markers to clinical swab samples as opposed to clinical isolates, since clinical samples contain mixed bacterial species, many of which are near neighbor species such as Neisseria meningitidis that can have the same mutations associated with AMR in NG. WGS could have confirmed the presence or absence of these mutations had viable NG been available for testing. These data also highlight the need for a rapid phenotypic assay for AMR surveillance, not just for NG, but for other pathogenic organisms that exhibit AMR.
Our molecular screening efforts for AMR in these samples were limited to markers for penicillin, ciprofloxacin, and ESCs, but assessments for resistance to other antibiotics, such as tetracycline (TetM) or azithromycin (23S rRNA mutations), could have provided valuable additional information. The molecular methods employed in this study were genotypic as opposed to phenotypic assays, and although the genotypic assay may detect a marker or SNP associated with AMR, the results do not necessarily correlate to phenotype. 21, 24 Treatment of NG infections in Nigeria is currently based on Centers for Disease Control and Prevention (CDC) guidelines, using a combination of intramuscular ceftriaxone and oral azithromycin, given the high percentages of observed macrolide-resistant NG, globally as well as in sub-Saharan Africa. Although the observation of NG strains resistant to ESCs remains rare, NG resistance to ESCs is expected to increase over time, and the implementation of routine screening efforts for AMR NG, either MICs, Etests, or a rapid phenotypic assay could provide valuable information that would inform therapy and potentially reduce treatment failures.
The percentages of resistance to penicillin and ciprofloxacin observed in this study highlight the need for continuous and consistent monitoring for AMR NG. This is particularly critical in populations and regions where transmission and acquisition of AMR NG is a concern, and where antibiotic stewardship is suboptimal. Molecular methods, despite their limitations can be useful tools in properly planned studies with appropriate sample types. Although these are not phenotypic assays, molecular methods represent the best intermediary approach until rapid, practical, affordable and accurate phenotypic assays are developed to monitor for AMR NG.
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